Background Vascular Ehlers-Danlos syndrome is a rare severe disease that causes arterial dissections and ruptures that can lead to early death. No preventive treatment has yet been validated. Our aim was to assess the ability of celiprolol, a beta(1)-adrenoceptor antagonist with a beta(2)-adrenoceptor agonist action, to prevent arterial dissections and ruptures in vascular Ehlers-Danlos syndrome. Methods Our study was a multicentre, randomised, open trial with blinded assessment of clinical events in eight centres in France and one in Belgium. Patients with clinical vascular Ehlers-Danlos syndrome were randomly assigned to 5 years of treatment with celiprolol or to no treatment. Randomisation was done from a centralised, previously establis...
Accumulating data from studies in animals and humans indicate that beta-blockade has antiatheroscler...
Celiprolol, a novel beta blocker, may be more effective than propranolol in unstable angina pectoris...
BACKGROUND: Effective inhibition of plasma kallikrein may have significant benefits for patients wit...
Background Vascular Ehlers-Danlos syndrome is a rare severe disease that causes arterial dissections...
Objecti_ Vascular Ehlers-Danlos syndrome (vEDS) is a rare monogenetic disease caused by pathogenic v...
IntroductionVascular Ehlers-Danlos syndrome (vEDS) is an autosomal dominant inherited disorder of co...
AIMS: Antihypertensive drugs are included in the medical therapy of vascular Ehlers-Danlos syndrome ...
Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist w...
Vascular Ehlers-Danlos syndrome is a rare inherited disorder caused by genetic variants in type III ...
International audience(1) Background: The vascular type of Ehlers–Danlos syndrome (vEDS) is a rare g...
Unlike patients with either hypertension (HT) of angina pectoris (AP) alone, patients with both HT a...
ObjectivesThe Heart Protection Study (HPS) provides an opportunity to assess directly the effects of...
Background: To assess the influence of β2-receptor suppression on top of selective β1-receptor block...
Background: Ehlers-Danlos syndrome (EDS) is a hereditary collagen vascular disorder characterized by...
In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality and morb...
Accumulating data from studies in animals and humans indicate that beta-blockade has antiatheroscler...
Celiprolol, a novel beta blocker, may be more effective than propranolol in unstable angina pectoris...
BACKGROUND: Effective inhibition of plasma kallikrein may have significant benefits for patients wit...
Background Vascular Ehlers-Danlos syndrome is a rare severe disease that causes arterial dissections...
Objecti_ Vascular Ehlers-Danlos syndrome (vEDS) is a rare monogenetic disease caused by pathogenic v...
IntroductionVascular Ehlers-Danlos syndrome (vEDS) is an autosomal dominant inherited disorder of co...
AIMS: Antihypertensive drugs are included in the medical therapy of vascular Ehlers-Danlos syndrome ...
Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist w...
Vascular Ehlers-Danlos syndrome is a rare inherited disorder caused by genetic variants in type III ...
International audience(1) Background: The vascular type of Ehlers–Danlos syndrome (vEDS) is a rare g...
Unlike patients with either hypertension (HT) of angina pectoris (AP) alone, patients with both HT a...
ObjectivesThe Heart Protection Study (HPS) provides an opportunity to assess directly the effects of...
Background: To assess the influence of β2-receptor suppression on top of selective β1-receptor block...
Background: Ehlers-Danlos syndrome (EDS) is a hereditary collagen vascular disorder characterized by...
In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality and morb...
Accumulating data from studies in animals and humans indicate that beta-blockade has antiatheroscler...
Celiprolol, a novel beta blocker, may be more effective than propranolol in unstable angina pectoris...
BACKGROUND: Effective inhibition of plasma kallikrein may have significant benefits for patients wit...